Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 11:17 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 61 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: FluLaval® Quadrivalent Clear all

Conditions: Influenza
Interventions: Fluzone Quadrivalent vaccine, no preservative (0.5-mL), 2019-2020 formulation, Fluzone High-Dose vaccine, 2019-2020 formulation; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 6 Months to 83 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 2
States / cities: Bardstown, Kentucky • Salt Lake City, Utah

Conditions: Influenza, Human
Interventions: Seasonal LAIV, Placebo, Wild-type A/California/2009-like Influenza Virus; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Healthy volunteers: Accepts healthy volunteers
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Vaccine Reaction
Interventions: MicronJet, Fluzone® Quadrivalent, Bacteriostatic Saline; Device · Biological · Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 40 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Influenza
Interventions: FluLaval® Quadrivalent, Fluzone®; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 6 Months to 35 Months
Enrollment: 316 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 12
States / cities: Sacramento, California • West Covina, California • Altamonte Springs, Florida + 9 more

Conditions: Influenza
Interventions: High-dose quadrivalent influenza virus vaccine, High-dose influenza virus vaccine, High-dose trivalent inactivated influenza vaccine; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 65 Years and older
Enrollment: 792 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 9
States / cities: Milford, Connecticut • Coral Gables, Florida • Wichita, Kansas + 6 more

Conditions: Vaccine Reaction
Interventions: MicronJet, Fluzone® Quadrivalent, Fluzone® High Dose Quadrivalent; Device · Biological
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 139 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Seasonal Influenza
Interventions: mRNA-1010, Fluarix®, Influsplit® Tetra, Fluarix Tetra, Alpharix® Tetra; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 40,805 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 188
States / cities: Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 150 more

Conditions: Influenza, Healthy
Interventions: Fluzone®, FluMist®; Biological
Lead sponsor: Stanford University; Other
Eligibility: 6 Months to 10 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Stanford, California

Conditions: Pain, Quality of Life, Injection Site Reaction, Adverse Drug Event
Interventions: FLUAD® Quadrivalent, Fluzone® High-Dose Quadrivalent, SHINGRIX®; Biological
Lead sponsor: Duke University; Other
Eligibility: 65 Years and older
Enrollment: 267 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: Baltimore, Maryland • Durham, North Carolina

Conditions: Influenza, Flu
Interventions: Fluzone Quadrivalent vaccine, Fluzone High-Dose vaccine; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 6 Months and older
Enrollment: 240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 3
States / cities: Council Bluffs, Iowa • Bardstown, Kentucky • Metairie, Louisiana

Conditions: Influenza
Interventions: Fluzone® Quadrivalent vaccine, 2014-2015 formulation, Fluzone I®ntradermal vaccine, 2014-2015 formulation, Fluzone High Dose vaccine, 2014-2015 formulation; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 208 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 4
States / cities: Santa Rosa, California • Council Bluffs, Iowa • Metairie, Louisiana + 1 more

Conditions: Influenza, Human
Interventions: Fluzone Quadrivalent, Flublok Quadrivalent; Biological
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 18 Years to 64 Years
Enrollment: 3,988 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 4
States / cities: Tucson, Arizona • Tallahassee, Florida • Houston, Texas + 1 more

Conditions: Influenza
Interventions: Flublok, Flucelvax, Fluarix, Fluzone, Fluzone High-Dose; Biological
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 944 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: Portland, Oregon • Temple, Texas

Conditions: Influenza
Interventions: FluMist; Biological
Lead sponsor: Stanford University; Other
Eligibility: 2 Years to 49 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Stanford, California

Conditions: Influenza Vaccine Effectiveness
Interventions: Not listed
Lead sponsor: MedImmune LLC; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 4,121 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 8
States / cities: Gainesville, Florida • Bloomington, Minnesota • Winston-Salem, North Carolina + 5 more

Conditions: Influenza
Interventions: Licensed 2010-2011 Trivalent Influenza Vaccine, No Preservative, Investigational Trivalent Influenza Vaccine with alternate B strain, No Preservative, Quadrivalent Influenza Vaccine, No Preservative; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 6 Months to 8 Years
Enrollment: 4,363 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 67
States / cities: Dothan, Alabama • Chandler, Arizona • Mesa, Arizona + 55 more

Conditions: Influenza
Interventions: Fluzone®, FluMist®; Biological
Lead sponsor: Stanford University; Other
Eligibility: 6 Months to 49 Years
Enrollment: 77 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Stanford, California

Conditions: Influenza Immunization, Healthy Volunteers
Interventions: Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2020-2021 formulation, Fluzone High-Dose Quadrivalent vaccine (0.7-mL dose), 2020-2021 formulation; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 6 Months to 84 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 2
States / cities: Bardstown, Kentucky • Salt Lake City, Utah

Conditions: Influenza, Hepatitis A, Typhoid, Healthy Adults
Interventions: Fluzone® quadrivalent, Fluzone High Dose, Fluad, Vaqta, Typhim Vi, Vivotif; Biological
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Stanford, California

Conditions: Immunization; Infection, Transplantation Infection, Influenza, Solid Organ Transplant
Interventions: High Dose Quadrivalent Inactivated Influenza Vaccine, Standard Dose Quadrivalent Inactivated Influenza Vaccine; Biological
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 396 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
Interventions: Quadrivalent VLP Vaccine, Fluarix Quadrivalent® Comparator Vaccine; Biological
Lead sponsor: Medicago; Industry
Eligibility: 65 Years and older
Enrollment: 12,794 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 50
States / cities: Mobile, Alabama • Tempe, Arizona • Banning, California + 42 more

Conditions: Influenza, Human
Interventions: NanoFlu, Fluzone Quadrivalent; Biological
Lead sponsor: Novavax; Industry
Eligibility: 65 Years and older
Enrollment: 2,654 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 19
States / cities: Hollywood, Florida • Savannah, Georgia • Stockbridge, Georgia + 16 more

Conditions: Influenza, Influenza Immunization
Interventions: Influenza Hemagglutinin mRNA vaccine, Quadrivalent Recombinant Influenza Vaccine; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 388 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 20
States / cities: Rolling Hills Estates, California • San Diego, California • Coral Gables, Florida + 14 more

Conditions: Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
Interventions: 15 µg/strain of Quadrivalent VLP Vaccine, 30 µg/strain of Quadrivalent VLP Vaccine, 15 µg/strain of the licensed quadrivalent vaccine; Biological
Lead sponsor: Medicago; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 900 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 3
States / cities: Hollywood, Florida • South Miami, Florida • Endwell, New York

Search by objective public record fields.

Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively

Safety and Effectiveness of a Seasonal Live Attenuated Influenza Vaccine in a Human Challenge Model of Infection With Wild-type (wt) Influenza A/California/2009 (H1N1)-Like Virus

Intradermal Influenza Vaccination- Healthy Cohort

Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine GSK2282512A When Administered to Children From 6 to 35 Months of Age

A Study of the Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Subjects Aged 65 Years and Older

Intradermal Influenza Vaccination

A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age

The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection

Simultaneous RZV and aIIV4 Vaccination

Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines

Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose, Influenza Vaccines in Adults

Recombinant Influenza Vaccine Versus Standard Egg-Based Inactivated Influenza Vaccine in Adults 18-64 Years

Immunogenicity Trial of Egg- Versus Non-Egg-Based Influenza Vaccines Among HCP

Response to Live Attenuated Influenza Vaccine in Tonsillar Tissues and Blood

A Case Control Study of the Effectiveness of Q/LAIV Versus Inactivated Influenza Vaccine and No Vaccine in Subjects 2-17 Years of Age

Study of Quadrivalent Influenza Vaccine Among Children

Innate and Acquired Immunity to Influenza Infection and Immunization (SLVP029)

Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2020-2021 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively

Effects of Aging on Primary and Secondary Vaccine Responses

High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients

Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly

Phase 3 Pivotal Trial of NanoFlu™ in Older Adults

Safety and Immunogenicity of a Monovalent mRNA Vaccine Encoding Influenza Hemagglutinin in Adult Participants 18 Years of Age and Older

Immunogenicity of a Quadrivalent Virus-Like Particles (VLP) Influenza Vaccine in Healthy Adults